Posted on by Shen Awards
59 / 100
Powered by Rank Math SEO
SEO Score

Assoc Prof Dr. Fatemeh Kazemi-Lomedasht | Medical Biotechnology | Best Researcher Award

Researcher of Pasteur Institute of Iran, Iran.

Fatemeh Kazemi-Lomedasht is an accomplished Associate Professor at the Biotechnology Research Center, Pasteur Institute of Iran. She holds a Ph.D. in Medical Biotechnology from Pasteur Institute and an M.Sc. in the same field from Tabriz University of Medical Sciences. Her research focuses on cancer biology, monoclonal antibodies, and drug delivery systems, particularly in developing nanobodies and targeted cancer therapies. She has authored numerous high-impact publications in journals such as TOXICON and Current Pharmaceutical Biotechnology. Her work includes innovative studies on nanobody development and targeted therapeutic strategies. Fatemeh is an active member of the American Chemical Society, Health Biotechnology Society, and Biotechnology Society, reflecting her engagement with the scientific community. Her contributions have advanced the field of biotechnology, and she continues to lead research efforts aimed at improving therapeutic and diagnostic applications.

Profile
Education

Fatemeh Kazemi-Lomedasht pursued her education in medical biotechnology with distinction. She completed her Ph.D. at the Pasteur Institute of Iran in 2015, where her dissertation focused on generating and selecting single-domain monoclonal antibodies (nanobodies) against vascular endothelial growth factor (VEGF) using phage display technology. This work contributed significantly to the field of targeted cancer therapies. Prior to her doctoral studies, she earned her M.Sc. in Medical Biotechnology from Tabriz University of Medical Sciences in 2011. Her master’s thesis investigated the anticancer properties of diferuloyl methane-containing nanoparticles and their effect on human telomerase reverse transcriptase gene expression in breast cancer cell lines. Both her Ph.D. and M.Sc. studies provided her with a strong foundation in molecular techniques, cancer research, and drug development, establishing her as a prominent researcher in her field.

Professional Experience

Fatemeh Kazemi-Lomedasht has had a distinguished career in the field of biotechnology. She has served as an Associate Professor at the Biotechnology Research Center of the Pasteur Institute of Iran since 2022, where she leads innovative research in cancer therapies, monoclonal antibodies, and drug delivery systems. Prior to this, she was an Assistant Professor at the same institution from 2015 to 2022, contributing significantly to the advancement of biotechnology research. During her tenure, she has been involved in groundbreaking studies on nanobodies and targeted cancer treatments, reflecting her expertise and leadership in the field. Her role includes overseeing research projects, mentoring junior researchers, and engaging with the scientific community. Fatemeh’s professional experience underscores her commitment to advancing biotechnological solutions and her influence in shaping research directions within her area of specialization

Research Interest

Fatemeh Kazemi-Lomedasht’s research interests are deeply rooted in advancing cancer research and biotechnology. Her work primarily focuses on the development and application of monoclonal antibodies and nanobodies for targeted cancer therapies, aiming to improve drug discovery and delivery methods. She is particularly interested in drug delivery systems that enhance the precision and efficacy of cancer treatments. Her research also delves into epitope mapping, which plays a crucial role in understanding protein interactions and designing targeted therapeutic agents. Kazemi-Lomedasht’s expertise extends to innovative approaches in developing functional nanobodies and evaluating their potential in combating various forms of cancer. Through her work, she seeks to contribute to the development of novel therapeutic strategies that can significantly impact cancer treatment and drug development, reflecting her commitment to advancing the field of biotechnology and improving patient outcomes.

Research Skills

Fatemeh Kazemi-Lomedasht possesses a comprehensive set of research skills crucial for advancing biotechnology. Her expertise encompasses a range of molecular techniques, including mammalian cell culture, isolation of primary cells, and cloning and expression of recombinant proteins. She is proficient in phage display technology, which has been pivotal in her work on generating and characterizing nanobodies. Additionally, Fatemeh is skilled in enzyme-linked immunosorbent assays (ELISA) and bioinformatics, which enhance her ability to analyze complex biological data. Her research frequently involves drug discovery and targeted delivery systems, reflecting her capability in designing and evaluating therapeutic agents. Her proficiency in these techniques, combined with her experience in epitope mapping and drug delivery research, highlights her ability to conduct high-impact research in the field of biotechnology and cancer therapeutics.

 Awards and Recognition

Fatemeh Kazemi-Lomedasht has garnered significant recognition for her contributions to the field of biotechnology. Her innovative research, particularly in monoclonal antibodies and drug discovery, has been well acknowledged in the scientific community. While specific awards are not listed, her impactful publications in high-profile journals such as TOXICON and Current Pharmaceutical Biotechnology highlight her contributions. Her work on nanobodies and targeted cancer therapies has been pivotal, reflecting her excellence in research. Additionally, her role as an Associate Professor at the Biotechnology Research Center of Pasteur Institute of Iran and her membership in prestigious scientific societies like the American Chemical Society, Health Biotechnology Society, and Biotechnology Society underscore her professional standing and influence. These achievements reflect her commitment to advancing biotechnology and her recognition as a leading researcher in her field.

Conclusion

Fatemeh Kazemi-Lomedasht is a highly qualified candidate for the Best Researcher Award, given her impressive research background, significant publications, and innovative contributions to biotechnology. Her strengths in cancer research and monoclonal antibodies are notable, and her role as an Associate Professor underscores her leadership in the field. Addressing areas for improvement, such as broadening the impact of her work and enhancing interdisciplinary collaboration, could further elevate her candidacy. Overall, her achievements and contributions make her a strong contender for this award.

Publications Top Notes

  • “Single-domain antibodies or nanobodies: a class of next-generation antibodies”
    • Authors: F Khodabakhsh, M Behdani, A Rami, F Kazemi-Lomedasht
    • Journal: International Reviews of Immunology
    • Year: 2018
    • Citations: 101
  • “Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody”
    • Authors: F Kazemi-Lomedasht, M Behdani, KP Bagheri, M Habibi-Anbouhi, …
    • Journal: Molecular Immunology
    • Year: 2015
    • Citations: 82
  • “Comparison of inhibitory effect of curcumin nanoparticles and free curcumin in human telomerase reverse transcriptase gene expression in breast cancer”
    • Authors: A Rami, N Zarghami
    • Journal: Advanced Pharmaceutical Bulletin
    • Year: 2013
    • Citations: 76
  • “Albumin nanoparticles as nanocarriers for drug delivery: Focusing on antibody and nanobody delivery and albumin-based drugs”
    • Authors: E Karami, M Behdani, F Kazemi-Lomedasht
    • Journal: Journal of Drug Delivery Science and Technology
    • Year: 2020
    • Citations: 74
  • “An overview on application of phage display technique in immunological studies”
    • Authors: A Rami, M Behdani, N Yardehnavi, M Habibi-Anbouhi, …
    • Journal: Asian Pacific Journal of Tropical Biomedicine
    • Year: 2017
    • Citations: 67
  • “The first report on transcriptome analysis of the venom gland of Iranian scorpion, Hemiscorpius lepturus”
    • Authors: F Kazemi-Lomedasht, V Khalaj, KP Bagheri, M Behdani, …
    • Journal: Toxicon
    • Year: 2017
    • Citations: 47
  • “Nanobodies as novel therapeutic agents in envenomation”
    • Authors: E Alirahimi, F Kazemi-Lomedasht, D Shahbazzadeh, M Habibi-Anbouhi, …
    • Journal: Biochemical and Biophysical Journal (BBA)-General Subjects
    • Year: 2018
    • Citations: 42
  • “Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)”
    • Authors: V Homayouni, M Ganjalikhani-Hakemi, A Rezaei, H Khanahmad, …
    • Journal: Iranian Journal of Basic Medical Sciences
    • Year: 2016
    • Citations: 41
  • “Development of a mono‐specific anti‐VEGF bivalent nanobody with extended plasma half‐life for treatment of pathologic neovascularization”
    • Authors: A Sadeghi, M Behdani, S Muyldermans, M Habibi‐Anbouhi, …
    • Journal: Drug Testing and Analysis
    • Year: 2020
    • Citations: 33
  • “Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function”
    • Authors: F Kazemi-Lomedasht, S Muyldermans, M Habibi-Anbouhi, M Behdani
    • Journal: Iranian Journal of Basic Medical Sciences
    • Year: 2018
    • Citations: 33
Fatemeh Kazemi-Lomedasht | Medical Biotechnology | Best Researcher Award

You May Also Like